Tauns Laboratories (TSE:197A) EBIT: 円173 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:197A Tauns Laboratories Inc TSE:197A
14 GF Score
Price 円484.00
! 6 Warning Signs
View Full Analysis

What is Tauns Laboratories EBIT?

Tauns Laboratories TSE:197A -0.82% 14 EBIT is 円173 Mil as of Dec. 2025. GuruFocus rates TSE:197A with a GF Score™ of 14/100. The stock has 6 warning signs investors should review.

Tauns Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was 円0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was 円173 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tauns Laboratories's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Tauns Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tauns Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.26%.

Tauns Laboratories  (TSE:197A) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tauns Laboratories's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (33014.04 + 37975.976)/ 2 )
=0/35495.008
=0.00 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=39084.063 - 1460.094 - ( 4609.929 - max(0, 9487.958 - 14863.475+4609.929))
=33014.04

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=44198.627 - 1967.433 - ( 4255.218 - max(0, 13148.932 - 18908.103+4255.218))
=37975.976

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Tauns Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (15464.81 + max(6960.811, 0)) + (15524.41 + max(10787.121, 0)) )/ 2 )
=0/( ( 22425.621 + 26311.531 )/ 2 )
=0/24368.576
=0.00 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2315.071 + 6811.567 + 1126.908) - (1460.094 + 0 + 1832.641)
=6960.811

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7207.36 + 6432.919 + 1012.606) - (1967.433 + 0 + 1898.331)
=10787.121

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tauns Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=173.128/67339.034
=0.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories EBIT Related Terms

Tauns Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Tauns Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories EBIT Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBIT
7,984.06 4,676.67 7,865.90 8,304.78

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,802.50 -1,057.83 556.94 0.00 674.02

TSE:197A vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Tauns Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tauns Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tauns Laboratories's EV-to-EBIT falls into.


TSE:197A
14GF Score
Tauns Laboratories Inc TSE:197A
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tauns Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円173 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円173 Mil mean?
Tauns Laboratories (TSE:197A) has a EBIT of 円173 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tauns Laboratories.
Is Tauns Laboratories' EBIT too high?
Tauns Laboratories' current EBIT is 円173 Mil. Overall, Tauns Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' EBIT compare to ISRG and BDX?
Tauns Laboratories' EBIT of 円173 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tauns Laboratories. Tauns Laboratories's current EBIT is 円173 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current EBIT of 円173 Mil. The current EBIT is 円173 Mil. Tauns Laboratories' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current EBIT is 円173 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tauns Laboratories Business Description

Address 761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
14GF Score

Get the complete analysis for TSE:197A

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円484.00
Price